GVR Report cover Extracorporeal CO2 Removal Devices Market Size, Share & Trends Report

Extracorporeal CO2 Removal Devices Market Size, Share & Trends Analysis Report By Application (ARDS, COPD), By Access (Venovenous, Arteriovenous), By End Use (ASCs, Clinics), By Product, And Segment Forecasts, 2021 - 2028

  • Published Date: Oct 2021
  • Report ID: GVR-4-68039-636-6
  • Number of Pages: 150
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019

Report Overview

The global extracorporeal CO2 removal devices market size was valued at USD 81.80 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 5.3% from 2021 to 2028. A rise in incidence of Acute Respiratory Distress Syndrome (ARDS) and Chronic Obstructive Pulmonary Disease (COPD) has led to the introduction of novel products for vitalizing blood flow and efficient gas exchange. An increasing number of regulatory product approvals for several extracorporeal removal devices during the COVID-19 pandemic helped various market players to increase their product sales. For instance, in April 2020, Alung Technologies received Emergency Use Authorization (EUA) from the U.S. FDA for Hemolung Respiratory Assist System (RAS) for the treatment of COVID-19.

Japan extracorporeal CO2 removal devices market size, by product, 2018 - 2028 (USD Million)

In recent times, COVID-19 disease caused by the novel coronavirus (SARS-CoV-2) has been a global severe prevalent problem and resulted in thousands of deaths. The respiratory manifestation was one of the main clinical characteristics of this disease, and approximately 15-20% of confirmed and suspected patients required mechanical ventilation and developed severe hypoxemia. The usage of extracorporeal CO2 removal devices has increased since the emergence of COVID-19. However, the number of ECMO machines was in a state of serious shortage for quite a long time during the peak period, along with specific ECCO2R devices.

With such increasing demand for these devices throughout the world, the market is projected to have significant growth during the forecast period. In recent years, several technological improvements and strategies have made it possible to reduce the complexity and size of extracorporeal CO2 removal devices. Various technical advances have made extracorporeal CO2 removal devices feasible and simple to use. Thus, technological advancements are anticipated to boost market growth.

These devices are used in patients with severe COPD exacerbation and for the establishment of ultraprotective or protective in patients suffering from ARDS. The devices eliminate blood CO2 and fight against the adverse effects of hypercapnia and related acidosis. According to the WHO, COPD has been considered the third leading cause of death globally and caused about 3.23 million deaths in 2019. In addition, according to the America Lung Association, more than 11 million people get diagnosed with COPD in the U.S. each year. Thus, rising cases of COPD are estimated to boost product adoption thereby augmenting the market growth.

Product Insights

The extracorporeal CO2 machines segment accounted for the largest revenue share of 52.3% in 2020. Technical simplification has caused the development and potential applications of extracorporeal CO2 extraction devices to progress rapidly, avoiding nearly some of the initial problems associated with ECMO. Extracorporeal CO2 removal devices are theoretically simpler and have fewer personnel as well as logistic requirements, leading to the increased preference among patients. Thus, increasing benefits associated with ECCO2R are anticipated to secure the market position.

The disposables segment is expected to grow at a significant CAGR of 4.87% over the forecast period. Disposables are used per procedures per patient basis in extracorporeal CO2 removal therapy. High consumption and demand for consumables in such procedures are predicted to augment the segment growth. Hence, the increasing need for disposables for several COPD- and ARDS-related procedures is anticipated to foster the demand for extracorporeal CO2 removal devices over the forecast period.

Access Insights

The venovenous segment accounted for the largest revenue share of 64.30% in 2020. In venovenous access, the blood is drawn from the central vein through a drainage cannula using a roller or centrifugal pump to produce flow across the gas exchange membrane. In recent years, a new generation of extracorporeal CO2 removal devices has been developed. Efficient venovenous extracorporeal CO2 removal devices are made available and are replacing the arterio-venous method, having the benefit of not requiring arterial puncture. Such a rise in product usage is projected to accelerate the segment growth.

The arteriovenous segment is estimated to register the fastest CAGR over the forecast years. With arteriovenous extracorporeal CO2 removal devices, the blood flows from the femoral artery with the help of a gas exchanger and returns into the contralateral femoral vein. Arteriovenous system uses a high-technology and simplified membrane lung characterized by high gas transfer efficiency, enormously low resistance to blood flow, and absence of a heat exchanger. Thus, the above-mentioned factors are anticipated to accelerate the segment growth.

End-use Insights

The hospitals segment captured the highest revenue share of over 46.36% in 2020. An increasing number of hospital admissions, especially the patients suffering from ARDS due to the recent outbreak of COVID-19, is predicted to boost the segment growth.Rising cases of COPD and ARDS are also anticipated to fuel the product demand in hospitals.

The Ambulatory Surgical Centers (ASCs) segment is projected to register significant CAGR from 2021 to 2028. This growth can be accredited to the rising cases of acute respiratory failure, especially in rural areas that have limited access to healthcare services. Moreover, ASCs offer better patient accessibility, lower out-of-pocket costs, and decreased facility costs. Thus, a high preference for ASCs is anticipated to fuel the segment growth.

Application Insights

The bridge to lung transplant segment accounted for the largest revenue share of more than 40% in 2020. Patients waiting for lung transplantation that develop life-threatening hypercarbia may benefit from extracorporeal CO2 removal devices by using them as a bridge to transplantation. The rising focus of manufacturers, such as Alung Technologies and Xenios AG, on developing extracorporeal CO2 removal devices for bridge to lung transplantation is anticipated to spur the market growth during the forecast period.

Global extracorporeal CO2 removal devices market share, by application, 2020 (%)

In patients with ARDS, these devices are in much demand owing to their ability to remove CO2 and help enable lung-protective ventilation through a reduction in plateau pressures and tidal volumes. These devices aid in the management of ARDS and allow more protective ventilation while eluding extreme levels of respiratory acidosis.

Regional Insights

Asia Pacific is anticipated to register the fastest CAGR of 7.24% during the forecast period. The presence of a large patient pool, rising awareness regarding acute respiratory failure, increasing government healthcare expenditure in developing countries, such as India and Japan, are predicted to accelerate the regional market growth. Supportive government initiatives and the success rate of extracorporeal CO2 removal devices during respiratory surgeries are said to foster market growth.

A huge population base with low per capita income in the region leads to high demand for affordable treatment options. Thus, multinational companies are looking forward to investing in developing countries, such as China, anticipating regional market growth. Improved healthcare infrastructure and high product adoption, especially during the COVID-19 pandemic, across the U.S. & Canada are projected to contribute to the North America regional market growth.

Early adoption of novel technologies and a large patient pool of ARDS and COPD are also anticipated to accelerate the regional market growth. In addition, increasing cases of chronic respiratory diseases are anticipated to create demand for extracorporeal CO2 removal devices. The rising preference for safe and rapid minimally invasive ventilation devices has also accelerated the market growth.

The market in Europe is expected to expand at the second-fastest CAGR of over 6% during the forecast period. Increasing demand for healthcare devices coupled with the rising prevalence of chronic diseases, such as respiratory failure, is expected to drive the regional market. Favorable reimbursement policies, increasing government investments in long-term healthcare, and growing healthcare research infrastructural framework are also boosting the market growth.

Key Companies & Market Share Insights

Novel product launches, product approvals, acquisitions, partnerships, and collaborations are major strategies adopted by companies to maintain their market share.  For instance, in May 2020, Alung Technologies announced the commercial development of the next-generation artificial lung. Hemolung Respiratory Assist System (RAS) extracorporeal CO2 removal devices are manufactured especially for this therapy. Some of the key players operating in the global extracorporeal CO2 removal devices market include:

  • Medtronic

  • Getinge AB

  • Xenios AG

  • Alung Technologies


  • Medica SpA

  • Aferectica Srl

Extracorporeal CO2 Removal Devices Market Report Scope

Report Attribute


Market size value in 2020

USD 82.81 million

Revenue forecast in 2028

USD 118.64 million

Growth rate

CAGR of 5.27% from 2021 to 2028

Base year for estimation


Historical data

2016 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, application, access, end use, and region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; India; Japan; China; Australia; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE

Key companies profiled

Medtronic; Getinge AB; Xenios AG; Alung Technologies; ESTOR SpA; Medica SpA; Aferectica Srl

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global extracorporeal CO2 removal devices market report on the basis of product, application, access, end use, and region:

  • Product Outlook (Revenue in USD Million, 2016 - 2028)

    • Extracorporeal CO2 Machines

    • Disposables

    • Others

  • Application Outlook (Revenue in USD Million, 2016 - 2028)

    • Acute Respiratory Distress Syndrome (ARDS)

    • Chronic Obstructive Pulmonary Disease (COPD)

    • Bridge to Lung Transplant

    • Others

  • Access Outlook (Revenue in USD Million, 2016 - 2028)

    • Venovenous

    • Arteriovenous

  • End-use Outlook (Revenue, USD Million, 2016 - 2028)

    • Hospitals

    • Ambulatory Surgical Centers

    • Clinics

    • Others

  • Regional Outlook (Revenue, USD Million, 2016 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

    • Asia Pacific

      • China

      • Japan

      • India

      • Australia

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.